Personal information

No personal information available

Activities

Employment (1)

Hospital Regional Universitario de Málaga: Malaga, MALAGA, ES

1999-12-19 to present | md, phd (medical oncology)
Employment
Source: Self-asserted source
manuel cobo

Education and qualifications (1)

Hospital Regional Universitario de Málaga: Malaga, malaga, ES

1999-12-18 to present | md, phd (medical oncology)
Qualification
Source: Self-asserted source
manuel cobo

Works (9)

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

Journal of Clinical Medicine
2023-08 | Journal article | Author
Contributors: Dolores Isla; Alfredo Sanchez-Hernandez; Joaquín Casal; manuel cobo; Margarita Majem Tarruella; Noemi Reguart; Jon Zugazagoitia; Reyes Bernabé
Source: check_circle
Multidisciplinary Digital Publishing Institute

Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade

Cancers
2023-06 | Journal article | Author
Contributors: oliver j; Juan Luis Onieva Zafra; María Garrido-Barros; manuel cobo; Beatriz Martínez-Gálvez; Ana Isabel García-Pelícano; Jaime Dubbelman; Jose Carlos Benitez; Juan Zafra Martín; Alejandra Cantero et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma

Biomedicines
2022-09 | Journal article | Author
Contributors: oliver j; Juan Luis Onieva Zafra; Maria Garrido-Barros; Miguel Angel Berciano Guerrero; Alfonso Sánchez-Muñoz; María José Lozano; Angela Farngren; Martina Álvarez Pérez; Beatriz Martínez-Gálvez; Elísabeth Pérez Ruiz et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade

International Journal of Molecular Sciences
2022-08 | Journal article | Author
Contributors: Juan Luis Onieva Zafra; Qingyang Xiao; Miguel Angel Berciano Guerrero; Aurora Laborda-Illanes; Carlos de Andrea; P Chaves; Pilar Piñeiro; Alicia Garrido-Aranda; Elena Gallego; Belén Sojo et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study

Cancers
2021-06 | Journal article | Author
Contributors: Sofía Ruiz-Medina; Silvia Gil; Begoña Jimenez; Pablo Rodriguez-Brazzarola; Tamara Diaz-Redondo; Mireya Cazorla; Marta Muñoz-Ayllon; Inmaculada Ramos; Carmen Reyna; María José Bermejo et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis

Journal of Clinical Medicine
2021-03 | Journal article | Author
Contributors: Margarita Majem Tarruella; manuel cobo; Dolores Isla; Diego Marquez-Medina; Delvys Rodriguez-Abreu; Joaquín Casal-Rubio; Teresa Moran Bueno; Reyes Bernabé-Caro; Diego Pérez Parente; Pedro Ruiz-Gracia et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response

Journal of Clinical Medicine
2020-01 | Journal article | Author
Contributors: Qingyang Xiao; André Nobre; Pilar Piñeiro; Miguel-Ángel Berciano-Guerrero; Emilio Alba; manuel cobo; Volker M Lauschke; Isabel Barragán
Source: check_circle
Multidisciplinary Digital Publishing Institute

Association of Circular RNA and Long Noncoding RNA Dysregulation to Clinical Response to Immunotherapy in Cutaneous Metastatic Melanoma

Source: check_circle
Multidisciplinary Digital Publishing Institute

High IGKC Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade

Source: check_circle
Multidisciplinary Digital Publishing Institute

Peer review (4 reviews for 2 publications/grants)

Review activity for Clinical & translational oncology. (3)
Review activity for Targeted oncology. (1)